tafluprost
Trade name: zioptan
Approved
Feb 10, 2012
Tafluprost acid is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and humans suggest that the main mechanism of action is increased uveoscleral outflow. A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Tafluprost was approved for use in the U.S. on February 10, 2012. Tafluprost, preserved and preservative-free formulations, received marketing approval for the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension in several European and Nordic countries as well as Japan, and some other Asia Pacific markets. — NCATS
Clinical trial activity
28 trials · 26 clinical orgs · 7 marketing orgs
Earliest trial started Sep 1, 2005 (NCT00918346)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 3 Sponsor(trial)
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
- Feb 10, 2012
Merck — Earliest FDA Approval
- Feb 10, 2012
Merck — NDA Organization
- Feb 10, 2012
Akorn, Inc. — NDA Secondary Org
- Feb 10, 2012
Akorn, Inc. — Marketing Organization
- Feb 10, 2012
Thea Pharma — Marketing Organization
- Feb 10, 2012
Thea Pharma — NDA Secondary Org
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
- Jun 4, 2018
Sandoz — Marketing Organization
- Aug 19, 2019
Micro Labs Ltd India — Marketing Organization
2020s
- Jan 28, 2022
Novartis — Marketing Organization
- Apr 5, 2024
Ingenus Pharmaceuticals — Marketing Organization
Indications
Mechanism of action
- Prostanoid FP receptorAGONIST
PTGFR agonist
Approval history
- approvedFeb 10, 2012
Chemistry & pharmacology
SMILES
CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC2=CC=CC=C2- Mol. weight
- 452.5313 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaTafluprost ↗
- NCATS1O6WQ6T7G3 ↗
- ChEMBLCHEMBL1963683 ↗
Also known as
- 1-methylethyl (5z)-7-((1r,2r, 3r,5s)-2-((1e)-3,3-difluoro-4-phenoxy -1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptenoate
- afp-168
- afp-168
- afp-168
- afp-168
- mk-2452
- mk-2452
- saflutan
- saflutan
- taflotan
- tafluprost
- tafluprost
- tafluprost
- tafluprost
- tafluprost
- tafluprost
- tafluprost
- tafluprost
- tafluprost
- tafluprost
- tafluprost
- tafluprost ophthalmic solution
- tapros
- zioptan
- zioptan
- zioptan
- zioptan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05299593 | Phase 4 | Jun 4, 2020 | Fondazione G.B. Bietti, IRCCS, University of Milan |
| NCT04654611 | Phase 4 | Feb 1, 2019 | Tun Hussein Onn National Eye Hospital |
| NCT03822559 | Phase 3 | Jan 20, 2019 | Santen Inc. |
| NCT04164459 | Phase 4 | Dec 19, 2018 | Taejoon Pharm Co., Ltd. |
| NCT03595865 | N/A | Aug 1, 2018 | Qingdao University |
| NCT04737928 | N/A | Apr 2, 2018 | Santen Inc. |
| NCT04455126 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2018 | Alexandria University |
| NCT03612817 | Phase 4 | Jan 31, 2017 | Aristotle University of Thessaloniki, Santen Inc. |
| NCT03204487 | Phase 4 | May 10, 2016 | Dr. Anton Hommer |
| NCT02471105 | Phase 4 | Sep 1, 2015 | Allergan, Katholieke Universiteit Leuven |
| NCT02802137 | Phase 4 | Mar 1, 2015 | Aristotle University of Thessaloniki |
| NCT02102750 | Phase 1 | Jun 1, 2014 | Santen Inc. |
| NCT01979913 | Phase 4 | Oct 1, 2013 | Dr. Anton Hommer |
| NCT01927406 | Phase 4 | Aug 1, 2013 | Stanford University |
| NCT01654484 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2012 | Santen Inc. |
| NCT01433900 | Phase 3 | May 1, 2012 | University of Milan |
| NCT01254604 | Phase 3 | Dec 1, 2011 | Merck |
| NCT01434888 | Phase 1 | Sep 1, 2011 | Santen Inc. |
| NCT01342081 | Phase 3 | May 1, 2011 | Santen Inc. |
| NCT01162603 | Phase 4 | Mar 1, 2011 | Aristotle University of Thessaloniki, University of Brescia |
Organizations
Research & Development (26)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Santen Inc. | For profit | 12 | 11 | 5 | 2005 |
| Aristotle University of Thessaloniki | Academic/Hospital | 3 | 2 | 1 | 2011 |
| Dr. Anton Hommer | Academic/Hospital | 2 | 2 | 1 | 2013 |
| FinnMedi Oy | For profit | 2 | 1 | 2 | 2008 |
| Merck | For profit | 2 | 2 | 1 | 2010 |
| University of Milan | Academic/Hospital | 2 | 1 | 2 | 2012 |
| University of Tampere | Academic/Hospital | 2 | 0 | 2 | 2010 |
| Alcon | For profit | 1 | 1 | 1 | 2009 |
| Alexandria University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Allergan | For profit | 1 | 0 | 1 | 2015 |
| Charles University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Fondazione G.B. Bietti, IRCCS | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Government of Finland | Government | 1 | 0 | 1 | 2010 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Medical University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Moscow State University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| P. Stradina Clinical University Hospital, Latvia | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Qingdao University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Semmelweis University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2013 |
Marketing (10)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Akorn, Inc. | For profit | NDA2 | Feb 10, 2012 |
| Akorn, Inc. | For profit | MKTG | Feb 10, 2012 |
| Ingenus Pharmaceuticals | For profit | MKTG | Apr 5, 2024 |
| Merck | For profit | NDA | Feb 10, 2012 |
| Micro Labs Ltd India | For profit | MKTG | Aug 19, 2019 |
| Novartis | For profit | MKTG | Jan 28, 2022 |
| Sandoz | For profit | MKTG | Jun 4, 2018 |
| Sandoz | For profit | SYN | Jan 28, 2022 |
| Thea Pharma | For profit | MKTG | Feb 10, 2012 |
| Thea Pharma | For profit | NDA2 | Feb 10, 2012 |